WuXi AppTec
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
💼Healthcare
👥501-1,000
WuXi AppTec

About WuXi AppTec

The company covers the development cycle through five core operations, including small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing a...

WuXi AppTec news and updates

WuXi AppTec partners with Wugen, Inc.

“WuXi AppTec is delighted to partner with Wugen to help make these life-saving cancer treatments less challenging to produce and more accessible to patients in need.”

Jan 1, 2022 | wuxiapptec.com

WuXi AppTec invested into assets : R&D and manufacturing facilities in the amount of $1.4B in Singapore, Singapore on Jul 19th 22'.

WuXi Biologics (HK; 2269) and WuXi AppTec ( OTCPK:WUXIF )( OTCPK:WUXAY ) (SHA: 603259) announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore.

Jan 1, 2022 | seekingalpha.com

WuXi AppTec is developing EDO platform

At PepGen, WuXi AppTec is developing its EDO platform to address these critical challenges by optimizing the tissue penetration, cellular uptake and nuclear delivery of oligonucleotides.

Jan 1, 2022 | wuxiapptec.com

WuXi AppTec expanded facilities to Singapore, Singapore on Jul 24th 22'.

WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site in Singapore.

Jul 17, 2022 | asiamanufacturingnewstoday.com

WuXi AppTec invested into assets : research and manufacturing facility in the amount of $1.4B in Singapore, Singapore on Jul 19th 22'.

And WuXi AppTec recently announced a $1.4 billion, 10-year project to build a research and manufacturing facility in Singapore.

Aug 24, 2022 | acs.org

WuXi AppTec received award Organization Company of the Year Award on Jan 1st 22'.

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced that it is a recipient of the 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a global research & consulting firm that helps customers accelerate growth.

Nov 29, 2022 | yahoo.com
See More